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a  b  s  t  r  a  c  t
A question is raised about an increased risk of severe infection from the use of biological
drugs  in patients with rheumatoid arthritis. This systematic review of observational studies
aimed at assessing the risk of severe infection associated with the use of anakinra, ritux-
imab,  and abatacept in patients with rheumatoid arthritis. The following databases were
searched: PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, Exerpta
Medica Database, Scielo, and Lilacs up to July 2010. Severe infections were deﬁned as those
life-threatening ones in need of the use of parenteral antibiotics or of hospitalization. Lon-
gitudinal observational studies were selected without language restriction, involving adult
patients diagnosed with rheumatoid arthritis and who used anakinra, rituximab, or abat-
acept. In four studies related to anakinra, 129 (5.1%) severe infections were related in 2896
patients, of which three died. With respect to rituximab, two studies reported 72 (5.9%)
severe infections in 1224 patients, of which two died. Abatacept was evaluated in only one
study in which 25 (2.4%) severe infections were reported in 1046 patients. The main site of
infection for these three drugs was the respiratory tract. One possible explanation for the
high  frequency of severe infections associated with anakinra may be the longer follow-up
time in the selected studies. The high frequency of severe infections associated with ritux-
imab  could be credited to the less strict inclusion criteria for the patients studied. Therefore,
infection monitoring should be cautious in patients with rheumatoid arthritis in use of thesethree  drugs.© 2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infecc¸ões  graves  em  pacientes  com  artrite  reumatoide  em  uso  de
anakinra,  rituximab  ou  abatacept:  revisão  sistemática  de  estudos
observacionais
Palavras-chave:
Artrite reumatoide/terapia
Antirreumáticos/efeitos adversos
Infecc¸ão
Terapia biológica/efeitos
adversos
Revisão de literatura como
assunto
r  e  s  u  m  o
Existe um questionamento sobre aumento do risco de infecc¸ões graves pelo uso de medica-
mentos biológicos por pacientes com artrite reumatoide. Esta revisão sistemática de estudos
observacionais objetivou avaliar o risco de infecc¸ões graves associadas ao uso de anakinra,
rituximab e abatacept em pacientes com artrite reumatoide. Foram pesquisadas as bases
PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, Exerpta Medica
Database, Scielo e Lilacs até julho/2010. Infecc¸ões graves foram deﬁnidas como aquelas
com de risco de vida, necessidade de antibióticos parenterais ou de hospitalizac¸ão. Foram
selecionados estudos observacionais longitudinais, sem restric¸ão de idioma, que envolviam
pacientes adultos com diagnóstico de artrite reumatoide que usaram anakinra, rituximab,
abatacept. Em quatro estudos relacionados ao anakinra, foram relatadas 129 (5,1%) infecc¸ões
graves em 2.896 pacientes, dos quais três evoluíram para óbito. Sobre o rituximab, dois estu-
dos relataram 72 (5,9%) infecc¸ões graves em 1.224 pacientes, dos quais dois evoluíram para
óbito. O abatacept foi avaliado em apenas um estudo, no qual foram relatadas 25 (2,4%)
infecc¸ões graves em 1.046 pacientes. O principal sítio de infecc¸ão para os três medicamen-
tos foi o trato respiratório. Uma possível explicac¸ão para a frequência elevada de infecc¸ões
graves associadas ao anakinra pode ser o maior tempo de acompanhamento nos estudos
selecionados. A frequência elevada de infecc¸ões graves associadas ao rituximab poderia ser
creditada ao critério menos restrito de inclusão de pacientes. Portanto, deve ser cautelosa
a  monitorac¸ão de infecc¸ões nos pacientes com artrite reumatoide que usam esses três
medicamentos.
©  2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
of unknown etiology that affects 0.5–1% of the world adult
population, predominantly in women, and with the highest
incidence in the age range of 30–50 years.1 The symmetric
polyarthritis characteristic of RA can cause pain and joint
destruction and deformity, especially in the joints of the hands
and wrists, as well as pain and systemic manifestations such
as fatigue, morning stiffness, and weight loss.2
RA patients may remain with active disease despite
the use of synthetic (or “non-biological”) Disease Modify-
ing Antirheumatic Drugs (DMARDs) such as methotrexate,
leﬂunomide, azathioprine, and cyclosporine. Thus, since 1997
new therapies, such as “biological DMARDs”, have been
employed, demonstrating greater efﬁcacy in the treatment of
RA,3 among which one can mention tumor- necrosis fac-
tor (TNF-)-antagonists (inﬂiximab, etanercept, adalimumab,
and golimumab) and non-TNF- antagonists (abatacept, rit-
uximab, anakinra, and tocilizumab) DMARDs.4
Some randomized controlled trials have shown an increase
in infection with the use of non-TNF-  antagonist DMARDs in
patients with RA, both with rituximab (5.2/100 patient-years
for methotrexate/rituximab association vs. 3.7/100 patient-
years for methotrexate only),5 as well as with abatacept (2.9%
for the association vs. 1.9% for methotrexate only).6 However,
other authors have not found this increase for rituximab,7
abatacept,8 or anakinra.9C BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Three systematic reviews (SRs) that evaluated non-TNF-
antagonist DMARDs were published.4,10,11
Gartlehner et al.10 have examined the comparative efﬁcacy
and safety of three TNF- antagonists and of a non-TNF-
antagonist (anakinra) for the treatment of rheumatoid arthri-
tis in 18 observational and experimental studies, but the
authors did not present results on infections.
Based on 12 clinical trials, Salliot et al.11 have suggested a
trend (not statistically signiﬁcant) for increased risk of severe
infection during the treatment with rituximab (odds ratio
[OR] = 1.45, conﬁdence interval [CI] 95%: 0.56–3.73), abatacept
(OR = 1.35; 95% CI: 0.78–2.32), and anakinra (OR = 2.75; 95% CI:
0.91–8.35).
Storage et al.,4 in a systematic review of eight (randomized
and open-label) clinical trials, identiﬁed severe infection in up
to 2.3% in cases of exclusive use of abatacept and from 1.3
to 12.7% with the use of abatacept associated with synthetic
DMARDs.
Although performing a meta-analysis of observational
studies on the safety of biological DMARDs, Bernatsky et al.12
studied only TNF- antagonists. Thus, we  emphasize that
except for abatacept, systematic reviews of observational
studies on the risk of severe infection associated with non-
TNF- antagonists (anakinra, rituximab, and tocilizumab)
have not yet been carried out.
The aim of this study was to evaluate the risk of severe
infection associated with the use of anakinra, rituximab,
abatacept, and tocilizumab in RA patients, using only obser-
vational studies.
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ethod
he description of this systematic review was conducted
ccording to a pre-speciﬁed protocol, based on the Preferred
eporting Items for Systematic Reviews and Meta-Analyses
PRISMA) guideline.13 The following are the main deﬁnitions
nd steps described in the protocol. Severe infections were
eﬁned as those in which there is a risk for the patient’s life,
nd the necessity of parenteral antibiotics or of hospitaliza-
ion in adult patients with RA users of anakinra, rituximab,
nd abatacept. Only longitudinal observational studies were
elected, including post-marketing evaluation studies and
linical trial follow-up studies (e.g., open-label clinical trials).
The following electronic databases were searched: PubMed,
iteratura Latino-Americana e do Caribe em Ciências da Saúde
LILACS), Scopus, Web of Science, Science Direct, Excerpta
edica Database (EMBASE), SciELO, and Scirus. For each
ase search, a strategy combining the following descrip-
ors – infection, bacterial infections, antirheumatic agents,
dverse effects, therapeutic use, rheumatoid arthritis, and
rug therapy – were developed. There were no restrictions
n language. The strategy used in Pubmed was: ((infec-
ion [MeSH Terms] OR bacterial infections [MeSH Terms])
ND (antirheumatic agents/adverse effects [MeSH Terms] OR
ntirheumatic Agents/therapeutic use [MeSH Terms])) AND
arthritis, rheumatoid/drug therapy [MeSH Terms]). Equivalent
trategies have been formulated for the other bases. The Scirus
ase also covered gray literature. Searches included studies
ublished up to July 2010, covering prior periods without lim-
tation of publication date. The reference lists of all articles
ere manually investigated, in a pursuit of new articles (cross-
eferences).
A database for the electronic searches was created with the
elp of the EndNote X1 program. Duplicate quotations were
eleted. Potentially relevant titles and abstracts were selected
ndependently by peer reviewers VPC/CAFA and VPC/SRLP,
ho  also took the readings of the full text, extracted informa-
ion, and assessed the quality of studies. Disagreements were
esolved by consensus and, where necessary, the opinion of
he third auditor (external to the pair of peer reviewers) was
equested.
The extraction of independent data was based on comple-
ing a standard form with relevant data about each study (full
eference, country of its production, sample size, design, dura-
ion, clinical and demographic characteristics of patients, the
esults for the risk of severe infection, and quality assessment
cores). The authors were contacted for data request needed
nd not contained in the published version of articles.
As to the interpretation of the frequency of severe infec-
ions, we  used the classiﬁcation proposed by Meyboom and
gberts14 for adverse drug reactions: commonly, when they
appen in 1–10% of users; unusually, 0.1–1%; and rarely, in less
han 0.1%.
To evaluate the quality of observational studies, an instru-
ent adapted, based on the Newcastle-Ottawa Scale,15 was
sed. Three items were considered; each received one point
hen the required standard was met: (1) manner of selec-
ion of participants – a described sample, representative of the
arget population by being complete, random or systematic; 6;5 6(6):543–550 545
(2) percentage of losses – with description, and under 20.0%;
and (3) manner of outcome assessment – an available or
described measuring instrument. In those articles that were
scored for the three items, the study was considered as being
of high quality; articles that received points for two  items were
considered of intermediate quality; and when only one item
was scored, the study was considered of low quality.
This study was approved by the Research Ethics Commit-
tee of the Instituto Nacional de Infectologia Evandro Chagas,
Oswaldo Cruz Foundation (Opinion 017/2010).
Results
A ﬂow chart (Fig. 1) describing the results of bibliographic
search performed was prepared. Initially, these searches in
eight databases provided 1583 abstracts, of which 19 were
selected for full-article reading. Apart from these abstracts, we
selected 44 of the 49 abstracts obtained by cross-references,
resulting in 63 full studies. Of these studies, only seven were
approved and included in the systematic review: ﬁve open-
label articles (Nuki et al.,16 Fleischmann et al.,17 Keystone
et al.,18 Genovese et al.,19 and Schiff et al.20), one cohort-nested
case–control study,21 and one cohort study22 (Fig. 1).
Table 1 presents the general characteristics of each study.
The seven observational studies included in this review had
a total duration of follow-up periods from six to 63 months,
were conducted in European countries, in the United States
(USA) and Mexico, and addressed 5166 patients diagnosed
with RA treated with one of three drugs (anakinra, rituximab,
abatacept). A meta-analysis was not performed due to the
presence of multiple sources of heterogeneity among studies,
and also to the limited number of publications for the studied
drugs (different types of study designs, eligibility criteria, and
medicines).
Anakinra
In total, 2896 patients were treated with anakinra and evalu-
ated in four studies lasting from 12 to 63 months: one cohort
study,22 two open-label articles,16,17 and one cohort-nested
case–control study21 (Table 1).
Among the evaluated patients, the female gender pre-
vailed, with a mean age from 52.8 to 54.8 years, with RA
duration ranging from four to 13 years, and with a very active
disease, according to the number of swollen or painful joints,
C-reactive protein, and a disease activity index based on 28
joints (DAS28 > 5.1). In those two articles that reported on
comorbidities,21,22 their authors observed mainly chronic lung
disease and diabetes mellitus. Concomitant use of cortico-
steroids ranged from 45.9% to 87.0%, and the use of various
synthetic DMARDs ranged from 71.4% to 80.5% (Table 2).
Brassard et al.21 only evaluated the risk of tuberculosis,
adding demographic data from the use of three biological
DMARDs (inﬂiximab, etanercept, and anakinra). Despite the
establishment of a contact with the author, there were no spe-
ciﬁc demographic data for anakinra, as well as for the sites of
infection.
Table 3 lists the four studies in which 147 episodes of
severe infection were reported in 129 (5.1%) of 2896 patients
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Identified abstracts in
electronic databases
(n=1583)
Cross-references
(n=49)
Screened abstracts
(n=1429)
Studies read in full
and assessed for
eligibility
(n=63)
Full studies excluded (n=56):
18 revisions
13 clinical trials
8 other medicines
4 without a diagnosis of rheumatoid arthritis
4 no information about infections
3 letters to the editor
3 case reports
2 not restricted only to rheumatoid arthritis
1 animal studies
Duplicates
removed
Id
en
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n
Sc
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g
Total of abstracts
(n=1632)
Excluded abstracts
(n=1366)
El
ig
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y
In
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ed
Included studies
(n=7)
(n=203)
f stuFig. 1 – Flowchart of selection o
treated with anakinra, along with their respective incidences
(frequencies and rates).The frequency of infection for anakinra ranged from 1.3
to 11.1%. Nuki et al.16 and Brassard et al.21 showed similar
frequencies (1.3%). Fleischmann et al.17 reported pneumonia
Table 1 – Description of the seven publications (2002–2009) on t
arthritis associated with use of non-anti-TNF- biological DMA
First author, year Drug Design 
Nuki,a 200216 Anakinra Open label 
Listing, 200522 Anakinra Cohort 
Brassard,b 200621 Anakinra Case–control nested in cohort 
Fleischmann,c 200617 Anakinra Open label 
Keystone, 200718 Rituximab Open label 
Genovese, 200919 Rituximab Open label 
Schiff, 200920 Abatacept Open label 
DMARDS, Disease Modifying Antirheumatic Drugs; USA, United States of A
a 218 in use of anakinra and 71 with placebo in the ﬁrst six months of th
open label (12 months).
b The outcome was tuberculosis.
c Patients who participated in the ﬁrst six months of the double-blind cldies for the systematic review.
(23.8%) and cellulitis (14.8%) as the most frequent infections,
but without detailing their clinical aspects. These authors
were the only ones who reported deaths related to the use of
anakinra. Nuki et al.16 did not specify the sites of the four cases
of severe infection and although these authors have informed
he risk of severe infections in patients with rheumatoid
RDs.
Place Sample size Duration of
study in
months
Europe (11 countries) 309 12–18
Germany 70 18
USA 1414 63
USA 1103 36
– 1039 6
9 international studies 185 12
USA, Europe and Mexico 1046 6
merica.
e double-blind clinical trial, all included in the extension phase with
inical trial and in the open-label phase for 30 months were included.
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Table 2 – Clinical and demographic characteristics of the samples of patients with rheumatoid arthritis in studies on the risk of severe infections associated with the
use of non-anti-TNF- biological DMARDS.
First author, year Drug Sample, n Women
(%)
Mean age
(SD)
Rheumatoid
arthritis
activity
Years  of
disease (SD)
Comorbidities
(%)
Corticosteroids,
n  (%)
Use  of
synthetic
DMARDs,
n (%)
Use of
synthetic
DMARDs,
n (SD)
Nuki, 200216 Anakinra 309 75.1 52.8 (13.0) NPJ 33.5 (13.1)
NSJ 25.9 (9.3)
CRP 3.9 (3.8)
4.0 (2.4) – 142 (45.9) 223c (72.2) 1.2c (1.0)
Listing, 200522 Anakinra 70 77.1 54.3 (11.6) 6.1 (1.2)a 13.0 (7.0–22.0)b Chronic lung
disease (12.9)
Diabetes (11.4)
Psoriasis (1.4)
61 (87.0) 50d (71.4) 4.2 (1.9)
Brassard, 200621 Anakinra 1414 – – – – Diabetes.
Silicosis
CKD. Solid organ
transplant and
carcinoma (. . .)
–  – –
Fleischmann,e 200617 Anakinra 1103 74.3 54.8 (19–85)f NPJ 22.2 (0–68)
NSJ 18.2 (0–66)
CRP 2.7 (0.1–25.6)
10.3 (0.2–59.5)f –g 654 (59.3) 888d (80.5) –
Keystone, 200718 Rituximab 1039 80.0 51.9 (11.4) 6.8 (1.0)a 11.2 (8.2) –h – – 2.5e (1.6)
Genovese, 200919 Rituximab 185 78.4 51.2 (12.3) 7.0 (0.9)a 11.9 (9.2) – – – 4.0f (2.4)
Schiff, 200920 Abatacept 1046 81.2 54.4 (12.4) 6.2 (0.7)a 11.6 (9.5) – 611 (58.4) 1003e (96.2) –
DMARDS, Disease Modifying Antirheumatic Drugs; SD, standard-deviation; NPJ, number of painful joints; NSJ, number of swollen joints; CRP, C-reactive protein; n, number.
a Arthritis rheumatoid activity by DAS28 (SD) – index of activity of the disease with 28 joints.
b Interquartile range.
c Prior use of non-biological DMARDs
d Concomitant use of non-biological DMARDs.
e Patients who participated in the ﬁrst six months of placebo-controlled clinical trial were included.
f (minimum and maximum).
g Diabetes and cancer excluded.
h Exclusion: changes in blood count, liver enzymes and creatinine.
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Table 3 – Results relative to the risk of severe infections associated with the use of non-anti-TNF- biological DMARDS in
patients with rheumatoid arthritis.
First author, year Drug Sample, n Infected patients
(number of
episodes)
Severe infections
% (95% CI)b
Rate of severe
infections/100
person-years
(95% CI)
Infection sites, n
(%)
Deaths, n
Nuki, 200216 Anakinra 309 4 (4) 1.3 (0.4–3.3) – – 0c
Listing, 200522 Anakinra 70 1 (2) 2.9 (0.4–9.9) 3.2 (0.4–11.5) Arthritis: 1
Acute
osteomyelitis: 1
0
Brassard, 200621 Anakinra 1414 19 (19) 1.3 (0.8–2.1) – – 0
Fleischmann,a
200617
Anakinra 1103 105 (122) 11.1 (9.3–13.1) 5.4 (4.5–6.4) Pneumonia: 29
Cellulitis: 18
Sepsis: 5
Other: 70
3  (sepsis)
Keystone, 200718 Rituximab 1039 – (59) 5.7 (4.4–7.3) 5.1 (4.0–6.6) UTI: –
Bronchitis: –
Sepsis: –
UTI: –
2  (bronchopneu-
monia and
sepsis)
Genovese, 200919 Rituximab 185 12 (13) 7.0 (3.8–11.7) 7.0 (4.1–12.0) Gastroenteritis:
4
Pneumonia: 2
Diverticulitis: 2
Bronchitis: 1
UTI: 2
Cellulitis: 1
Septic arthritis:
1
0
Schiff, 200920 Abatacept 1046 25 (25) 2.4 (1.6–3.5) – Pneumonia: 6
Bronchitis: 3
0
CI 95%, conﬁdence interval of 95%; URTI, upper respiratory tract infection; UTI, urinary tract infection.
a Patients who participated in the ﬁrst six months of the placebo-controlled clinical trial were included.
her’s
 not ab The WinPepi program was used for calculations, with 95% CI, Fis
c The author of this article reported the occurrence of two deaths
two deaths, they did not consider anakinra as a causal fac-
tor. Listing et al.22 reported a patient who developed septic
arthritis, which progressed to osteomyelitis.
Three studies17,21,22 were classiﬁed as of intermediate qual-
ity, and a fourth study received a low-qualiﬁcation16 (Table 4).
Rituximab
Rituximab was administered in 1224 patients evaluated in
two open-label clinical trials with durations from six18 to 1219
months (Table 1). Here too female gender prevailed, with a
mean age of 51.8 years, with high RA activity, according to
DAS28 (>5.1), and with a mean disease duration ranging from
11 to 12 years (Table 2).
Table 3 lists the two studies related to rituximab in which
72 episodes of severe infection (5.9%) were reported in the
total number of patients treated, and the highest incidence
was noted in the study by Genovese et al.19 These infections
occurred in various sites, particularly upper respiratory tract
(URT), urinary tract, and gastrointestinal tract.
Although Keystone et al.18 have not speciﬁed all severe
infection sites, these authors reported two deaths attributed
to the use of rituximab: one of them due to bronchopneumo-
nia and the other due to neutropenic sepsis after the use of
trimethoprim. exact test.
ttributed to anakinra.
Both studies18,19 were classiﬁed as high-quality trials
(Table 4).
Abatacept  and  tocilizumab
Only an open-label clinical trial lasting six months evaluated
abatacept.20 The authors included 1046 patients with similar
characteristics as to gender, age, and RA duration and activ-
ity reported in the studies related to anakinra and rituximab.
Pneumonia and bronchitis were the main types of infection
observed (Tables 2 and 3). The quality of the Schiff et al.20
study was considered intermediate (Table 4). In the period of
the review, no observational study evaluated infections in RA
patients taking tocilizumab.
Discussion
This revision compiled information of 5166 RA patients tak-
ing anakinra, rituximab, or abatacept, of which at least 166
had severe infections – 5.1% with anakinra, 5.9% with ritux-
imab,  and 2.4% with abatacept, with events characterized as
common.14 Only one study included16 was considered of low
quality, and the remaining trials had scored for at least two  of
the three evaluated quality criteria.
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Table 4 – Quality assessment of selected studies on the risk of severe infections in patients with rheumatoid arthritis
associated with the use of non-anti-TNF- biological DMARDs using an instrument based on the Newcastle-Ottawa Scale.
Assessment of each item (selection of participants, losses, outcome, and selection of variables) and of the total score.
First author, year Selection of participantsa Lossesb Outcomec Total score
Nuki, 200216 1 0 0 1
Listing, 200522 1 0 1 2
Brassard, 200621 1 0 1 2
Fleischmann, 200617 1 0 1 2
Keystone, 200718 1 1 1 3
Genovese, 200919 1 1 1 3
Schiff, 200920 1 1 0 2
DMARDs, Disease Modifying Antirheumatic Drugs.
a Selection of participants – 1 point for described sample representative of the population (complete, random or systematic).
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The strengths of this review consist of the wide search con-
ucted, of the broad deﬁnition of severe infections, and of
ts originality, taking into account that, although other SRs
rom observational studies have been published, such stud-
es do not separately evaluate these same drugs. We  detected
nly one review23 of observational studies that, although
ssessing the safety of the therapeutic drugs evaluated in this
tudy, presented their results collectively, also including TNF-
ntagonists.
Curtis et al.24 described a cohort (1998–2011) in which the
ates of severe bacterial infections associated with the use
f rituximab were 4.4 (95% CI 3.1–6.4) and, for abatacept, 2.8
95% CI 1.7–4.7), per 100 patient-years. Our results were similar
ince the frequency of infection was also higher for rituximab
ersus abatacept.
A meta-analysis published by Singh et al.,25 which evalu-
ted severe infection in patients with RA treated with nine
iologic drugs, included these three medications studied in
ur SR, but the authors did not include observational studies
nd presented collective results for the nine drugs, showing
n increase in severe infections with the use of biologicals in
onventional doses (OR = 1.90; 95% CI 1.50–2.39).
The incidence of infections related to the use of abatacept
n this study (2.4%), possibly due to the short follow-up period
six months) of the single identiﬁed trial,20 was similar to the
ncidence found by Salliot et al.11 (2.5%) in a randomized trial
asting 12 months.26
In this SR, severe infection rates for anakinra were hetero-
eneous, ranging from 1.3% in the smaller follow-up studies
Nuki et al.16 – 12 months, and Listing et al.22 – 18 months)
o 11.1% in the study with the largest sample (1103 patients)
nd with a 36-month follow-up.17 In an SR that included four
linical trials with a six-month duration, Salliot et al.11 found
nly 1.4% of severe infections.
In the studies included in our SR which evaluated
ituximab,18,19 the follow-up times, of six to 12 months, were
imilar to those of the three trials included by Salliot et al.11
hus, the highest frequency of severe infections attributed by
s to rituximab could be partially credited to the inclusion cri-
erion of Keystone et al.,17 who admitted patients diagnosed
ith diabetes mellitus, unlike the case in Salliot et al.’s SR.11
In the comparison of our SR versus SRs published by Salliot
t al.11 and Storage et al.,4 we  observed that the respiratorysurement instrument.
tract is the main site of infection with respect to anakinra and
abatacept. However, with the use of rituximab, urinary and
gastrointestinal tracts (in addition to the respiratory tract) are
also main sites of severe infection, both in our SR as in Salliot
et al.11
The number of published observational studies on adverse
events with the use of non-TNF-  antagonist DMARDs is
scarce. This is a limitation that affects the present review and
also other published reviews on this topic.11,27
We  emphasize that in addition to the fact that severe infec-
tions have occurred with a frequency considered as common,
these infections have resulted in deaths (three in 125 severe
infections with anakinra, two in 72 with rituximab, and zero
with abatacept). If we take into account that the maximum
follow-up time in most of the studies analyzed was only about
three years, not allowing the observation of a greater number
of fatal cases, we emphasize the importance of SRs to the clin-
ical practice of rheumatology. Considering the risk of severe
infections brought about by these drugs, patients should have
their respiratory and urinary tracts regularly monitored with
an active surveillance for infections, particularly those more
severe ones, in order to prevent conditions such as bronchop-
neumonia or sepsis.
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